Nav: Home

Reprogramming pancreatic cancer

July 03, 2019

Findings published today in the journal Science Translational Medicine suggest that a type of white blood cell called tumor associated macrophages (TAMs) that have been deceived by pancreatic cancer cells into not attacking them can be "re-programmed" by a specially designed molecule that activates a protein found on their surfaces.

Researchers hope that this immune system boosting molecule -- ADH-503--can eventually also make the checkpoint inhibitor immunotherapies that revolutionized the treatment of many cancers available to pancreatic cancer patients. Pancreatic cancer is the third deadliest cancer in the United States, but has shown to not respond to most current immunotherapies.

The paper "Agonism of CD11b reprograms innate immunity to sensitize pancreatic cancer to immunotherapies" was collaboration between Washington University School of Medicine in St. Louis and Rush University Medical Center in Chicago. Co-senior authors are David DeNardo, PhD, an associate professor of medicine and of pathology and immunology at Washington University and Vineet Gupta, PhD, of Rush's Vice Chair for Research and Innovation in the Department of Internal Medicine.

The authors describe how the novel ADH-503 compound interferes with the migration and polarization of myeloid cells - a type of immune system cell that circulates through the body identifying and attacking pathogens like cancer. One type of myeloid cell called macrophages (Greek for "big eaters") that are present in the tumors were a particular focus, as cancer cells are especially adept at disrupting the processes in which macrophages are able to control tumor growth.

In myeloid cells, including macrophages, a receptor protein called CD11b plays a central role in recruiting them to tumors and in detecting threats and signaling whether the immune system should respond. In pancreatic cancer tumors, the number of macrophages that help tumors grow far outnumber those that suppress them.

ADH-503 binds with and activates the CD11b receptor proteins on the myeloid cell surface. When the researchers orally delivered the ADH-503 compound to mice with pancreatic cancer, the number of myeloid cells in and near the tumors dropped, and the remaining myeloid cells were shown to be ones that promoted, rather than suppressed, immune responses. This environment translated into greater numbers of cancer-killing T cells in the tumor, significantly slower tumor growth and longer survival.

"We believe these data demonstrate that targeting the CD11b receptor with a novel molecule can decrease TAM density and reprogram myeloid cell responses to reduce tumor growth. It also overcomes resistance to T-Cell mediated therapies." Dr. Gupta said.

The researchers then investigated whether creating this same environment could make pancreatic tumors susceptible to standard immunotherapy. First, they treated a control group of mice with checkpoint inhibitor (PD-1 inhibitor) immunotherapy used to treat other kinds of cancer. There was no measurable effect. But when the therapy was combined with the ADH-503 compound, the tumors shrank and the mice survived significantly longer.

While pancreatic cancer is the third leading cause of cancer-related death in the United States, only 89 of more than 2,600 (or about 3%) 2,600 cancer immunotherapies clinical trials target pancreatic cancer

"Pancreatic cancer is a highly lethal disease and we are in desperate need of new therapeutic approaches," said DeNardo. "In animal studies, this small molecule led to very marked improvements and was even curative in some cases. We are hopeful that this approach could help pancreatic cancer patients."
-end-
Phase 1 clinical trials are planned by Gossamer Bio, Inc for the middle of this year.

Rush University Medical Center

Related Cancer Articles:

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.
Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.
Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.
Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.
More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.
New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.
American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.
Oncotarget: Cancer pioneer employs physics to approach cancer in last research article
In the cover article of Tuesday's issue of Oncotarget, James Frost, MD, PhD, Kenneth Pienta, MD, and the late Donald Coffey, Ph.D., use a theory of physical and biophysical symmetry to derive a new conceptualization of cancer.
More Cancer News and Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Debbie Millman: Designing Our Lives
From prehistoric cave art to today's social media feeds, to design is to be human. This hour, designer Debbie Millman guides us through a world made and remade–and helps us design our own paths.
Now Playing: Science for the People

#574 State of the Heart
This week we focus on heart disease, heart failure, what blood pressure is and why it's bad when it's high. Host Rachelle Saunders talks with physician, clinical researcher, and writer Haider Warraich about his book "State of the Heart: Exploring the History, Science, and Future of Cardiac Disease" and the ails of our hearts.
Now Playing: Radiolab

Insomnia Line
Coronasomnia is a not-so-surprising side-effect of the global pandemic. More and more of us are having trouble falling asleep. We wanted to find a way to get inside that nighttime world, to see why people are awake and what they are thinking about. So what'd Radiolab decide to do?  Open up the phone lines and talk to you. We created an insomnia hotline and on this week's experimental episode, we stayed up all night, taking hundreds of calls, spilling secrets, and at long last, watching the sunrise peek through.   This episode was produced by Lulu Miller with Rachael Cusick, Tracie Hunte, Tobin Low, Sarah Qari, Molly Webster, Pat Walters, Shima Oliaee, and Jonny Moens. Want more Radiolab in your life? Sign up for our newsletter! We share our latest favorites: articles, tv shows, funny Youtube videos, chocolate chip cookie recipes, and more. Support Radiolab by becoming a member today at Radiolab.org/donate.